BRENNEN MEDICAL, LLC – Trademark Portfolio

Entity Type: 16

BRENNEN MEDICAL, LLC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include XENMATRIX, E · Z DERM, and GLUCAN PRO. The owner is based in ST. PAUL, MN.

1290 HAMMOND ROAD

ST. PAUL, MN 55110

11 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BRENNEN MEDICAL, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (10 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does BRENNEN MEDICAL, LLC have?

BRENNEN MEDICAL, LLC has 11 U.S. trademarks filed with the USPTO. Of these, 4 registered, 7 cancelled.

What trademark classes does BRENNEN MEDICAL, LLC file in?

BRENNEN MEDICAL, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BRENNEN MEDICAL, LLC's most well-known trademarks?

BRENNEN MEDICAL, LLC's registered trademark portfolio includes well-known marks such as XENMATRIX, E · Z DERM, and GLUCAN PRO. These are among 4 currently registered trademarks in the portfolio.

What is BRENNEN MEDICAL, LLC's trademark registration success rate?

BRENNEN MEDICAL, LLC has a 36% trademark registration rate, with 4 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.